Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association
- 1 January 2022
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 42 (1), E48-E60
- https://doi.org/10.1161/atv.0000000000000147
Abstract
High levels of lipoprotein(a) [Lp(a)], an apoB100-containing lipoprotein, are an independent and causal risk factor for atherosclerotic cardiovascular diseases through mechanisms associated with increased atherogenesis, inflammation, and thrombosis. Lp(a) is predominantly a monogenic cardiovascular risk determinant, with ≈70% to ≥90% of interindividual heterogeneity in levels being genetically determined. The 2 major protein components of Lp(a) particles are apoB100 and apolipoprotein(a). Lp(a) remains a risk factor for cardiovascular disease development even in the setting of effective reduction of plasma low-density lipoprotein cholesterol and apoB100. Despite its demonstrated contribution to atherosclerotic cardiovascular disease burden, we presently lack standardization and harmonization of assays, universal guidelines for diagnosing and providing risk assessment, and targeted treatments to lower Lp(a). There is a clinical need to understand the genetic and biological basis for variation in Lp(a) levels and its relationship to disease in different ancestry groups. This scientific statement capitalizes on the expertise of a diverse basic science and clinical workgroup to highlight the history, biology, pathophysiology, and emerging clinical evidence in the Lp(a) field. Herein, we address key knowledge gaps and future directions required to mitigate the atherosclerotic cardiovascular disease risk attributable to elevated Lp(a) levels.Keywords
This publication has 123 references indexed in Scilit:
- Genetic Associations with Valvular Calcification and Aortic StenosisThe New England Journal of Medicine, 2013
- Genetic Evidence That Lipoprotein(a) Associates With Atherosclerotic Stenosis Rather Than Venous ThrombosisArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- Associations Between Lipoprotein(a) Levels and Cardiovascular Outcomes in Black and White SubjectsCirculation, 2012
- Lipoprotein(a), Inflammation, and Peripheral Arterial Disease in a Community-Based Sample of Older Men and Women (the InCHIANTI Study)The American Journal of Cardiology, 2010
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular MortalityJAMA, 2009
- Catalysis of Covalent Lp(a) Assembly: Evidence for an Extracellular Enzyme Activity that Enhances Disulfide Bond FormationBiochemistry, 2006
- Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus.JCI Insight, 1997
- Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice.JCI Insight, 1997
- The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans.JCI Insight, 1995
- cDNA sequence of human apolipoprotein(a) is homologous to plasminogenNature, 1987